<DOC>
	<DOCNO>NCT02531061</DOCNO>
	<brief_summary>Since biological disease-modifying anti-rheumatic drug ( bDMARDs ) available rheumatoid arthritis ( RA ) strategy emerge question definition remission RA . Today criterion already propose last one propose 2011 . All criterion integrate clinical criterion without image assessment . In context , ultrasound joint daily perform without definition remission . A discrepancy exist clinical remission persistence active disease ultrasound joint presence Doppler effect indicate inflammation risk progression joint damage . A definition remission RA could include erosion regression subchondral bone ( best measure high resolution peripheral quantitative compute tomography ( HR-pQCT ) ) . The main hypothesis reduction erosion size assess HR-pQCT observe absence local inflammation measure Doppler ultrasound erosion . Tumor Necrosis Factor ( TNF ) blocker strongly improve RA therapy outcome term clinical improvement structural damage ( progression radiographic lesion ) . Recent data show could joint bone rebuilt case inflammation suppression . HR-pQCT new technique emerge bone erosion assessment RA . Erosions size volume could reduce anti-TNF , large interindividual variability . There correlation activity clinical ultrasound synovium evolution erosion HR-pQCT .</brief_summary>
	<brief_title>Impact Persistence Inflammation Doppler Ultrasound Level Structural Evolution Erosion Rheumatoid Arthritis Treated With Biotherapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Initial medical examination perform , RA diagnosis accord criterion ACR / EULAR 2010 Low moderate disease activity DAS28 ≤ 4 since least 6 month Patients bDMARDs ( Remicade® , Enbrel® , Humira® , Cimzia® , Simponi® , RoActemra® , ou Orencia® ) since least 6 month change plan investigator , Patient least one erosion head 2nd 3rd metacarpal right leave , Stable corticosteroid dose since least 3 month less equal 10 mg prednisone equivalent , Medical care monitor rheumatology department CHU SaintEtienne Edouard Herriot Hospital Lyon , write consent patient Other diagnosis RA , Intravenous intraarticular injection 2nd 3rd metacarpophalangeal leave right 3 month prior inclusion , Surgery provide 2nd 3rd metacarpophalangeal right leave within year inclusion , Concomitant treatment zoledronic acid ( Aclasta ) denosumab ( Prolia® ) Refusal blood collection , Pregnancy breastfeed woman ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>bDMARDs</keyword>
	<keyword>biotherapy</keyword>
	<keyword>remission</keyword>
	<keyword>erosion</keyword>
</DOC>